Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()

Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our object...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Ugolkov, Andrey, Qiang, Wenan, Bondarenko, Gennadiy, Procissi, Daniel, Gaisina, Irina, James, C. David, Chandler, James, Kozikowski, Alan, Gunosewoyo, Hendra, O'Halloran, Thomas, Raizer, Jeffrey, Mazar, Andrew P.
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2017
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5496477/
https://ncbi.nlm.nih.gov/pubmed/28672195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.06.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars